<?xml version='1.0' encoding='utf-8'?>
<document id="27022468"><sentence text="Inhaled loxapine and intramuscular lorazepam in healthy volunteers: a randomized placebo-controlled drug-drug interaction study."><entity charOffset="8-16" id="DDI-PubMed.27022468.s1.e0" text="loxapine" /><entity charOffset="35-44" id="DDI-PubMed.27022468.s1.e1" text="lorazepam" /><pair ddi="false" e1="DDI-PubMed.27022468.s1.e0" e2="DDI-PubMed.27022468.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27022468.s1.e0" e2="DDI-PubMed.27022468.s1.e1" /></sentence><sentence text="Pharmacodynamic effects and safety of single-dose inhaled loxapine administered via the Staccato(®) system and intramuscular (IM) lorazepam in combination versus each agent alone were compared in a randomized, double-blind, crossover study in healthy volunteers"><entity charOffset="58-66" id="DDI-PubMed.27022468.s2.e0" text="loxapine" /><entity charOffset="130-139" id="DDI-PubMed.27022468.s2.e1" text="lorazepam" /><pair ddi="false" e1="DDI-PubMed.27022468.s2.e0" e2="DDI-PubMed.27022468.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27022468.s2.e0" e2="DDI-PubMed.27022468.s2.e1" /></sentence><sentence text=" Subjects received: inhaled loxapine 10 mg + IM lorazepam 1 mg; inhaled loxapine 10 mg + IM placebo; IM lorazepam 1 mg + Staccato placebo in random order, each separated by a 3-day washout"><entity charOffset="28-36" id="DDI-PubMed.27022468.s3.e0" text="loxapine" /><entity charOffset="72-80" id="DDI-PubMed.27022468.s3.e1" text="loxapine" /><pair ddi="false" e1="DDI-PubMed.27022468.s3.e0" e2="DDI-PubMed.27022468.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27022468.s3.e0" e2="DDI-PubMed.27022468.s3.e1" /></sentence><sentence text=" Primary endpoints were maximum effect (minimum value) and area under the curve (AUC) from baseline to 2 h post treatment for respirations/min and pulse oximetry" /><sentence text=" Least-squares means (90% confidence interval [CI]) for concomitant treatment versus each agent alone were derived and equivalence (no difference) confirmed if the 90% CI was within 0" /><sentence text="8-1" /><sentence text="25" /><sentence text=" Blood pressure (BP), heart rate (HR), sedation (100-mm visual analog scale), and adverse events (AEs) were recorded" /><sentence text=" All 18 subjects (mean age, 20" /><sentence text="4 years; 61% male) completed the study" /><sentence text=" There was no difference between inhaled loxapine + IM lorazepam and either agent alone on respiration or pulse oximetery during the 12-h postdose period, confirmed by 90% CIs for AUC and C min ratios" /><sentence text=" BP and HR were no different for inhaled loxapine + IM lorazepam and each agent alone over a 12-h postdose period" /><sentence text=" Although the central nervous system sedative effects were observed for each treatment in healthy volunteers, the effect was greater following concomitant lorazepam 1 mg IM + inhaled loxapine 10 mg administration"><entity charOffset="183-191" id="DDI-PubMed.27022468.s13.e0" text="loxapine" /></sentence><sentence text=" There were no deaths, serious AEs, premature discontinuations due to AEs, or treatment-related AEs" /><sentence text=" " /></document>